Q4 2024 Altimmune Inc Earnings Call Transcript
Key Points
- Altimmune Inc (ALT) has completed enrollment in its phase 2b trial for pemvidutide in MASH, with top-line data expected in Q2 2025.
- The company has submitted INDs for pemvidutide in two additional indications, both cleared by the FDA, allowing phase 2 trials to start in mid-2025.
- Altimmune Inc (ALT) has a strong cash position of USD 132 million, expected to fund operations into the second half of 2026.
- The company plans to hold a virtual R&D Day to disclose additional indications and provide a detailed overview of new opportunities.
- Altimmune Inc (ALT) has strengthened its board with the addition of experienced pharmaceutical industry professionals, Terry Lauer and Jerry Durso.
- The company reported a net loss of USD 95 million for the year 2024, an increase from USD 88 million in 2023.
- R&D expenses increased significantly to USD 82.2 million in 2024 from USD 65.8 million in 2023.
- There is uncertainty regarding the FDA's stance on non-invasive tests (NITs) for phase 3 trial designs in MASH.
- The retirement of Chief Medical Officer Scott Harris in early 2026 may lead to a transition period and potential disruption.
- The company faces competitive pressure in the MASH and obesity markets from other drugs and programs, such as GLP-1s and FGF 21s.
Good day, ladies and gentlemen, and welcome to Altimmune fourth quarter and full year 2024 financial results conference call. As a reminder, this call is being recorded. (Operator Instructions)
I would now like to introduce your host for today's conference call, Lee Roth, President of President, Burns Mcclellan Investor Relations, advisor to Altimmune. Lee, you may begin.
Thanks Gigi. Good morning everyone, and once again thank you all for joining us for Altimmune fourth quarter and full year 2024 financial results and business update conference call.
On today's call, you'll hear from Dr. Vipin Garg, our Chief Executive Officer, Dr. Scot Harris, our Chief Medical Officer, and Greg Weaver, our Chief Financial Officer. Dr. Scott Roberts, our Chief Scientific Officer, and Ray Jordt, our Chief Business Officer, will join us for the Q&A session.
Press release covering our fourth quarter and full year 2024 financial results and corporate update was issued earlier this morning
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
